单细胞多组学（SCM-Omics）和空间多组学（SM-Omics）技术为探索组织/器官中细胞类型的组成和功能提供了先进的方法。自2009年以来，单细胞RNA测序（scRNA-seq）已取得许多突破性的新发现。将这一方法与SM-Omics技术的出现和发展相结合，已成为神经科学、发育生物学和癌症研究等领域的开创性策略，特别是对于评估肿瘤异质性和T细胞浸润。近年来，这些方法在代谢疾病研究中的应用也有所增加。新兴的SCM-Omics和SM-Omics方法允许对细胞的分子和空间分析，以探索调控状态和确定细胞命运，从而为揭示异质性代谢过程并使其可干预提供了有希望的工具。本文回顾了SCM-Omics和SM-Omics技术的发展，并描述了在与代谢相关疾病中应用SCM-Omics和SM-Omics取得的进展，包括肥胖症、糖尿病、非酒精性脂肪肝（NAFLD）和心血管疾病（CVD）。我们还得出结论，应用SCM-Omics和SM-Omics方法可以帮助解析代谢疾病发病机制的分子机制，促进代谢相关疾病的治疗措施。本综述以对这一新兴领域的现状和未来前景的概述作为结束。© 2023年 作者。

Single-cell multi-Omics (SCM-Omics) and spatial multi-Omics (SM-Omics) technologies provide state-of-the-art methods for exploring the composition and function of cell types in tissues/organs. Since its emergence in 2009, single-cell RNA sequencing (scRNA-seq) has yielded many groundbreaking new discoveries. The combination of this method with the emergence and development of SM-Omics techniques has been a pioneering strategy in neuroscience, developmental biology, and cancer research, especially for assessing tumor heterogeneity and T-cell infiltration. In recent years, the application of these methods in the study of metabolic diseases has also increased. The emerging SCM-Omics and SM-Omics approaches allow the molecular and spatial analysis of cells to explore regulatory states and determine cell fate, and thus provide promising tools for unraveling heterogeneous metabolic processes and making them amenable to intervention. Here, we review the evolution of SCM-Omics and SM-Omics technologies, and describe the progress in the application of SCM-Omics and SM-Omics in metabolism-related diseases, including obesity, diabetes, nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). We also conclude that the application of SCM-Omics and SM-Omics approaches can help resolve the molecular mechanisms underlying the pathogenesis of metabolic diseases in the body and facilitate therapeutic measures for metabolism-related diseases. This review concludes with an overview of the current status of this emerging field and the outlook for its future.© 2023 The Authors.